Article Text

PDF
FRI0763-HPR Investigating the clinical and cost burden of primary sjÖgren's syndrome: a descriptive analysis from a us administrative claims database
  1. S Perera1,
  2. L Ma2,
  3. R Punwaney3,
  4. S Ramachandran4
  1. 1GSK, London, United Kingdom
  2. 2GSK, Pennsylvania
  3. 3GSK, New York
  4. 4GSK, King of Prussia, United States

Abstract

Background There is limited information available describing the disease burden of primary Sjögren's Syndrome (pSS).

Objectives This retrospective cohort study aimed to provide a descriptive analysis of the clinical characteristics and disease burden of patients with pSS and describe their healthcare resource use and associated costs.

Methods This retrospective cohort study (HO-15–16077) was conducted in the US Truven MarketScan® Commercial database. This database reports descriptive data from employees and their families, as covered by employer-sponsored private health insurance. The primary cohort comprised patients with ≥1 diagnosis of sicca syndrome prior to 1 January 2013, and continued enrolment for ≥24 months (1 January 2012 to 31 December 2013). Patients with any conditions mimicking sicca symptoms not due to SS were excluded, as were those with connective tissue disease that may suggest secondary SS. The 1:1 matched comparator population comprised subjects without a previous diagnosis of sicca syndrome (sicca-free). The primary objective was to describe the clinical characteristics and demographics of patients with pSS, including the proportion of patients with glandular versus extra-glandular disease. The secondary objective was to describe their healthcare costs and resource utilisation compared with sicca-free subjects.

Results There were 12,717 eligible patients in the primary cohort: the majority (86%) were female and the mean age was 51 years. Overall, 61% of patients had claims associated with extra-glandular disease manifestations. These patients experienced a higher disease burden with 41% reporting pain, fatigue and/or insomnia, compared with 12% of patients with glandular disease only who reported pain, fatigue and/or insomnia. Patients in the primary cohort incurred greater annual healthcare service costs (1.6 times greater for all causes and 1.5 times greater for pSS-related causes) and healthcare resource utilisation compared with the sicca-free comparator cohort. The largest difference in SS-related resource utilisation was in the number of office visits (primary cohort: 5.8 visits per patient; comparator cohort: 4.7 visits per patient). Patients with extra-glandular disease also incurred greater average annual costs and used more healthcare resources than patients with glandular disease only.

Conclusions Despite treatment, patients with pSS still experience a high disease burden. Here we have provided novel insights into the higher treatment cost and increased healthcare utilisation burden of pSS compared with the sicca-free cohort, in particular for patients with extra-glandular disease manifestations.

Acknowledgements Study funded by GSK. Jennie Frain, PhD, Fishawack Indicia Ltd, UK, provided editorial assistance funded by GSK

Disclosure of Interest S. Perera Shareholder of: GSK, Employee of: GSK, L. Ma Shareholder of: GSK, Employee of: GSK, R. Punwaney Shareholder of: GSK, Employee of: GSK, S. Ramachandran Shareholder of: GSK, Employee of: GSK

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.